SCHEMBL3083764

SCHEMBL3083764

Oc1nc(Cl)cc2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM4 Q8TD43 1/20 0.45
NQO2 P16083 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 2/20 0.39
HIF1A Q16665 1/20 0.39
CYP1B1 Q16678 1/20 0.39
KDM4E B2RXH2 3/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
HPGD P15428 2/20 0.38
MAPT P10636 2/20 0.38
MPI P34949 1/20 0.38
CYP1A2 P05177 3/20 0.38
CYP2A6 P11509 1/20 0.38
GLA P06280 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALOX5 P09917 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29601221 0.77 L3MBTL1 (0.46) TRPM4NQO2L3MBTL1ALDH1A1HSD17B10
SCHEMBL162040 0.77 TRPM4 (0.48) TRPM4NQO2L3MBTL1ALDH1A1HSD17B10
SCHEMBL9629001 0.77 TRPM4 (0.48) TRPM4NQO2ALDH1A1HSD17B10HIF1A
SCHEMBL165745 0.77 L3MBTL1 (0.46) TRPM4NQO2L3MBTL1ALDH1A1HSD17B10
SCHEMBL23860797 0.74 F12 (0.47) NQO2L3MBTL1ALDH1A1HSD17B10HIF1A
SCHEMBL2170888 0.74 CYP2A6 (0.47) L3MBTL1ALDH1A1HSD17B10HIF1ACYP1B1
SCHEMBL29091622 0.74 L3MBTL1 (0.43) TRPM4NQO2L3MBTL1ALDH1A1HSD17B10
SCHEMBL1133961 0.74 TRPM4 (0.45) TRPM4NQO2ALDH1A1HSD17B10HIF1A
SCHEMBL14913815 0.74 TRPM4 (0.45) TRPM4NQO2ALDH1A1HSD17B10HIF1A
SCHEMBL28347820 0.74 TRPM4 (0.45) TRPM4NQO2L3MBTL1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 US disclosed
EP-3354643-B1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE AERIE PHARMACEUTICALS INC (US) 2020-10-28 EP disclosed
EP-3354643-A1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE Aerie Pharmaceuticals, Inc. (US) 2018-08-01 EP disclosed
EP-3053913-B1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE AERIE PHARMACEUTICALS INC (US) 2018-03-07 EP disclosed
US-8278442-B2 Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders PROSIDION LIMITED (GB) 2012-10-02 US disclosed
EP-1505963-B9 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-09-21 EP disclosed
EP-1505963-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-04-20 EP disclosed
US-20100173886-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-07-08 US disclosed
EP-2152671-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2010-02-17 EP disclosed
WO-2008142454-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2008-11-27 WO disclosed
WO-2006000085-A1 HEPATITIS C INHIBITOR PEPTIDE ANALOGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-01-05 WO disclosed
US-6172268-B1 REACTING A HYDROXY AROMATIC COMPOUND WITH A PROPYLENE OXIDE IN PRESENCE OF METAL COMPLEX CATALYST ASAHI GLASS COMPANY, LIMITED (JP) 2001-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173886-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS OPRM1, OPRK1, OPRD1 TRPM4 966/4885NQO2 1955/4885L3MBTL1 1621/4885
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 TRPM4 2347/4885NQO2 859/4885L3MBTL1 41/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 TRPM4 2347/4885NQO2 859/4885L3MBTL1 41/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 TRPM4 2347/4885NQO2 859/4885L3MBTL1 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.